Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01517555
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
  • placebo — DRUG
    Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
  • paracetamol — DRUG
    One single dose of 1 g. Tablet

Study Details

This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial glucose.

Key Dates

Start date
Oct 31, 2006
Status verified
Jan 2017
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
18 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
  • Placebo Comparator: Placebo

Primary Outcome Measure

Area under the curve of paracetamol

Related Studies